Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0028754 (
obesity
)
124,988
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Surveys of the apparently healthy working population of the West of Scotland have revealed a high prevalence of hyperlipoproteinaemia (HIP). In males, type IV occurred more frequently (12%) than in females (3.3%), although
obesity
played an important part in this finding.
HLP
also occurred frequently (61%) in survivors of myocardial infarction (type II 39%, type IV 22%) but less frequently in peripheral vascular disease (38%), although there was a higher prevalence in females (47%) than males (32%) largely due to an increased prevalence of type IIa (29.5% cf 7.5%).
HLP
did not appear to play a significant role in cerebrovascular disease.
...
PMID:The prevalence of hyperlipoproteinaemia in vascular disease. 21 84
The basal levels of cholesterol (CS), triglycerides (TG), sugar, immunoreactive insulin (IRI), cortisol, testosterone, triiodothyronine (T3) and thyroxine (T4) were compared in 116 healthy males with risk factors of developing coronary heart disease (CHD), aged 45, engaged in administrative activities associated with stress and hypokinesia, with relation to normo-, hyperlipoproteinemia (NLP and
HLP
) and percentage of excessive body mass (IBM). In NLP as well as in
HLP
with an increase in IBM a tendency to elevated levels of CS, TG, sugar, IRI was noted, however there was no direct parallelism. In both cases the IBM value within the limits of
obesity
, I degree, did not influence the concentration of blood cortisol and testosterone. T3 and T4 levels were significantly decreased in males with IBM exceeding the normal one by 25%. They demonstrated the highest content of blood CS, TG and sugar on an empty stomach.
...
PMID:[Relationship of the value of excess body weight to the blood concentration of cholesterol and triglycerides and the level of the basic hormones regulating lipid metabolism in healthy men 30 to 50 years old]. 382 9
The influence of the efficacy of triglyceride and cholesterol correction on cardiovascular complications and mortality was analysed in a follow-up study with 260 patients with primary
HLP
(triglycerides before entry greater than 2.9 mmol/l and/or cholesterol greater than 7.8 mmol/l). The follow-up time was 67.4 +/- 27 months. It was hypothesised that reduction of elevated levels of triglycerides and/or cholesterol influenced favourably the incidence of angina pectoris, MI, stroke and total mortality. For ethical reasons, it was not possible to carry out the investigations with a control group. Therefore, we performed an internal comparison of 3 categories of lipid correction achieved during the trial (effective, moderate, insufficient). A substantial improvement of the lipid disorder was obtained by individualizing the therapy. Triglycerides and cholesterol decreased on average by 50% and 20%, respectively. The incidence of MI was 10 times higher than in the general population. With respect to the type of
HLP
, hypertriglyceridemia revealed a significantly higher incidence of MI compared with hypercholesterolemia and mixed
HLP
. The therapy variant was only of importance with respect to gallstone diseases accumulating in the CPIB-treated subgroups. We found a majority of cases with newly manifested angina pectoris and stroke in the group with moderate correction of both triglycerides and cholesterol. Patients with effective triglyceride and cholesterol correction suffered less frequently from MI than those with insufficient correction. This was also the case with secondary prevention in cases with MI prior to entry. There was no significant difference in the distribution of lipid categories at entry between those with and without recurrent infarction. In the group without reinfarction, however, the percentage with insufficient control diminished significantly. Associated risk factors such as hypertension, diabetes, smoking and
obesity
were of minor or no significance. In subjects with effective triglyceride correction, the total mortality was 0.97/1000 treatment months vs. 3.63 in insufficiently treated patients. The figures for MI mortality were 0.36 and 1.91, respectively.
...
PMID:Reduced incidence of cardiovascular complications and mortality in hyperlipoproteinemia (HLP) with effective lipid correction. The Dresden HLP study. 649 44
In 86 patients with primary
HLP
type IV over 50% were detected at systematical examinations of non-commissioned officers so that the number of male patients is uncommonly very high, 80, (93%). The highest number of patients--66 (92,5%) belonged to the age group 41-60 years. The analysed group showed the increased incidence of:
obesity
(60,5%), disturbed glycoregulation (45,3%), arterial hypertension (34,9%), ischemic heart disease (26,7%), hyperuricemia (23%), occlusive peripheral artery disease (16,3%), low values of serum cholesterol concentration LVG (X = 0,98 mmol/l), markedly decreased fibrinolytic activity (eugolobulin fibrinolysis 240 +/- 29 min) and hyperinsulinism (in 9 of 13 patients). Eruptive xanthomas were found in 7 (8,1%) patients. Due to male predominance the incidence of cholelithiasis is lower than expected (8,1%).
...
PMID:[Clinical characteristics of primary hyperlipoproteinemia type IV. An analysis of 86 patients]. 696 34
Subjects with abdominal obesity are characterized by hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis. Food intake, particularly at noon, is a well-known inducer of HPA axis activation. Whether obese subjects present an abnormal response to meals containing different macronutrient proportions is at present unknown. Therefore, this study was carried out to investigate the effect of a high-lipid/protein meal (HLP-meal) and a high-carbohydrate meal (HCHO-meal) on the HPA axis activity in women with different
obesity
phenotypes. Nondepressed, noncomplicated obese (body mass index greater than 28 kg/m(2)) women with abdominal (A-BFD) (n = 10) and peripheral body fat distribution (P-BFD) (n = 9) and a group of 11 normal-weight controls were investigated in the follicular phase of the menstrual cycle. They were randomly given an 800-kcal HCHO-meal (containing 89% carbohydrates, 11% proteins, 0% lipids), and an 800-kcal
HLP
-meal (containing 53% lipids, 43% proteins, 4% carbohydrates), which were eaten within 15 min at noon, with an interval of 2 d between each meal. Blood samples for ACTH, cortisol, glucose, and insulin were obtained at 15-min intervals before and after each meal. Baseline hormone and glucose concentrations in the three groups were similar. After the
HLP
-meal, ACTH tended to similarly but insignificantly increase in all groups, whereas cortisol increased significantly (P < 0.05) in the P-BFD group and insignificantly in the other groups. Conversely, both ACTH and cortisol significantly (P < 0.05) increased only in the A-BFD group, without any significant changes in both controls and P-BFD women. The analysis of the interaction between meals and groups clearly indicated that the cortisol response to the
HLP
-meal and the HCHO-meal was significantly different (P < 0.025) between the two obese groups, the A-BFD group being characterized by a significantly lower response to the
HLP
-meal and a significantly higher response to the HCHO-meal, compared with the P-BFD group. Considering all groups together and after adjusting for body mass index, a highly significant relationship was found between cortisol-area under the curve and ACTH-area under the curve after each meal test. However, no relationships were found between changes in ACTH and cortisol and those of glucose, insulin, and the glucose:insulin ratio after each meal. Therefore, our data demonstrate that the response of the HPA axis to meals containing different macronutrient proportions may depend on the pattern of body fat distribution. We also suggest that the activation of the HPA axis following the ingestion of large amounts of carbohydrates may have some pathophysiological relevance, specifically in women with the abdominal obesity phenotype.
...
PMID:Comment: response of the hypothalamic-pituitary-adrenocortical axis to high-protein/fat and high-carbohydrate meals in women with different obesity phenotypes. 1216 47
Cardiovascular diseases (CVD) represent a significant health problem in all countries world-wide and in the developed world, including the Czech Republic, in particular. The underlying cause in the majority of CVD patients is atherosclerosis and its complications, respectively. The present paper focuses on prevention and timely treatment of atherosclerosis. Management should be comprehensive and should target the risk factors (RF). Hypertension, hyperlipoproteinaemia and dyslipidemia (
HLP
and DLP), type 2 diabetes mellitus (T2DM), visceral fat
obesity
and cigarette smoking are the dominating RFs. Even though all RFs have to be managed simultaneously and it is not possible to focus on just one of them, for the sake of clarity, this paper discusses hypertension and the use of telmisartan, a representative of one the most up-to-date group of antihypertensives. There is a growing evidence that it is not always just a reduction of a specific risk that is important but also the mode of treatment. For example, to reduce a CV risk in a patient with hypertension but also, for example, with metabolic syndrome, it is more beneficial to treat the patient with rennin-angiotensin system (RAS) blocking agents, possibly in a combination with calcium channels antagonists, than to use "traditional" (older) treatment approach with a combination of a beta/blocker and diuretic. Among the RAS-modifying agents, ACE inhibitors and sartans are the most widely used. Among sartans, telmisartan is very well-tolerated and has evidence from a large interventional study for its effect on reducing the CV risk.
...
PMID:[Comprehensive management of cardiovascular risk. Focusing on telmisartan]. 2084 16
We report the restoration of euglycaemia in chemically induced diabetic C57BL/6 mice and spontaneously diabetic Non
Obese
Diabetic (NOD) mice by intravenous systemic administration of a single-stranded adeno-associated virus (ssAAV2/8) codon optimised (co) vector encoding furin cleavable human proinsulin under a liver-specific promoter. There were no immunological barriers to efficacy of insulin gene therapy in chemically induced C57BL/6 mice, which enjoyed long-lasting correction of hyperglycaemia after therapy, up to 250 days. Euglycaemia was also restored in spontaneously diabetic NOD mice, although these mice required a 7-10-fold higher dose of vector to achieve similar efficacy as the C57BL/6 mice and the immunodeficient NOD
scid
mice. We detected CD8
+
T cell reactivity to insulin and mild inflammatory infiltration in the livers of gene therapy recipient NOD mice, neither of which were observed in the treated C57BL/6 mice. Efficacy of the gene therapy in NOD mice was partially improved by targeting the immune system with anti-CD4 antibody treatment, while transfer of NOD mouse AAV2/8-reactive serum to recipients prevented successful restoration of euglycaemia in AAV2/8-
HLP
-hINSco-treated NOD
scid
mice. Our data indicate that both immune cells and antibodies form a barrier to successful restoration of euglycaemia in autoimmune diabetic recipient mice with insulin gene therapy, but that this barrier can be overcome by increasing the dose of vector and by suppressing immune responses.
...
PMID:Immunosuppression overcomes insulin- and vector-specific immune responses that limit efficacy of AAV2/8-mediated insulin gene therapy in NOD mice. 3051 69